Intellia Therapeutics price target lowered to $50 from $60 at Wells Fargo
Wells Fargo lowered the firm’s price target on Intellia Therapeutics (NTLA) to $50 from $60 and keeps an Overweight rating on the shares. Most ...
First Solar price target lowered to $236 from $273 at Barclays
Barclays lowered the firm’s price target on First Solar (FSLR) to $236 from $273 and keeps an Overweight rating on the shares following the ...